APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? Tatsuo KandaGeorge K. K. LauMasao Omata Guidelines Open access 11 December 2018 Pages: 103 - 109
Serum ferritin as a biomarker for NAFLD: ready for prime time? Raj A. ShahKris V. Kowdley Editorial 09 February 2019 Pages: 110 - 112
Immunological cure of HBV infection Julia LangChristoph Neumann-HaefelinRobert Thimme Review Article 02 January 2019 Pages: 113 - 124
Goals and targets for personalized therapy for HCC Thomas CouriAnjana Pillai Review Article 01 January 2019 Pages: 125 - 137
Laser capture microdissection: techniques and applications in liver diseases Beatriz Aguilar-BravoPau Sancho-Bru Review Article 01 January 2019 Pages: 138 - 147
Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection Lung-Yi MakDanny Ka-Ho WongMan-Fung Yuen Original Article 22 January 2019 Pages: 148 - 156
The impact of national viral hepatitis therapy program and hepatitis B vaccination program on mortality from acute and chronic viral hepatitis in Taiwan Shih-Yung Su Original Article 31 January 2019 Pages: 157 - 164
Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated? Amr Shaaban HanafyMohamed A. BassionyMohammad Abd Alkhalik Basha Original Article 13 February 2019 Pages: 165 - 172
Sofosbuvir–velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India Ajit SoodAjay DusejaVivek Saraswat Original Article Open access 21 February 2019 Pages: 173 - 179
Plasminogen activator inhibitor 2 (PAI2) inhibits invasive potential of hepatocellular carcinoma cells in vitro via uPA- and RB/E2F1-related mechanisms Ye JinZhi-Yong LiangLi Zhou Original Article 01 January 2019 Pages: 180 - 189
Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy? Ashokkumar JainDanielle MillerZakiyah Kadry Original Article 24 January 2019 Pages: 190 - 198
The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting Shuntaro ObiTakahisa SatoMasao Omata Original Article 22 January 2019 Pages: 199 - 204
Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005–2016 Donghee KimWon KimAijaz Ahmed Original Article 29 January 2019 Pages: 205 - 213
Mutations in CYP2C9 and/or VKORC1 haplotype are associated with higher bleeding complications in patients with Budd–Chiari syndrome on warfarin Akash ShuklaAbhinav JainShobna Bhatia Original Article 08 January 2019 Pages: 214 - 221
Serum ferritin level is associated with liver steatosis and fibrosis in Korean general population Ju Young JungJae-Jun ShimChang-Mo Oh Original Article 04 September 2018 Pages: 222 - 233
Influence of proton pump inhibitors on microbiota in chronic liver disease patients Kenta YamamotoMasatoshi IshigamiYoshiki Hirooka Original Article 08 February 2019 Pages: 234 - 244